- The distribution component unlocks a new revenue source for the company, helping drive future growth
- MINDCURE’s platform was built as a digital tool and distribution platform, and has already been used for deployment and distribution of ketamine for depression and pain
- Digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021 at a CAGR of 31.4 %, a substantial increase primarily driven by the COVID-19 pandemic and the stressors associated with it
- MINDCURE’s target areas and value proposition list numerous benefits for therapists, patients, payers, and drug and protocol developers, through the proprietary technology and platform.
A recent non-binding Letter of Intent (“LOI”) was signed between Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, and Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF), a biotech company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction. Under the LOI, MINDCURE becomes a distributor of Awakn’s ketamine-assisted psychotherapy for Alcohol Use Disorder in the United States and Canada, through its proprietary digital therapeutics platform, iSTRYM.
This is MINDCURE’s first international partnership with industry leaders developing rigorous psychedelics protocols and drugs that can be distributed through the company’s platform to support both therapists and patients. As well as distributing its partners’ protocols, the company will also be distributing its own protocols through iSTRYM.
With the minimum viable product (“MVP”) version of iSTRYM already released into partner clinics across North America, the company expects to partner with 75 clinics in both Canada and the U.S. when beginning full commercia deployment in early 2022, and to double that number by Q4 2022. The distribution component of iSTRYM opens up a new source of revenue for the company, which will help fuel further growth and expansion strategies.
MINDCURE’s digital therapeutics (“DTx”) platform was built to be scaled at a global level as a drug-agnostic digital tool and distribution platform. The company’s own protocols of ketamine for depression and ketamine for pain have already been created, with ketamine for an undisclosed indication currently in development.
With additional revenue to drive growth goals, the company expects to be able to leverage multiple emerging opportunities on the fast-growing digital therapeutics market. Globally, the digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021, at a CAGR of 31.4% (https://ibn.fm/ARbYX).
DTx is a subdivision of digital health, but not all digital health solutions are DTx. According to the Digital Therapeutics Alliance, DTx deliver evidence-based therapeutic interventions that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies, to optimize patient care and health outcomes. The rise in DTx can be attributed to the mass use of smart devices by consumers. Another element that has driven the demand for digital therapies has been the COVID-19 pandemic, with its associated stressors and increase in mental health conditions.
A variety of segments stand to benefit from DTx and MINDCURE’s proprietary platform – therapists, patients, payers, and drug and protocol developers. Each segment has its own value proposition, according to the company:
- Therapist Value Proposition:
- Cost reduction
- More favorable outcomes
- An increased portfolio of protocols that can expand guidance on practice and payer code guidance
- Patient Value Proposition
- Improved compliance
- Outcomes are optimized
- Proofing of the safety and efficacy
- Payer Value Proposition
- Access to cumulative data on the patient outcomes and compliance
- Drug and Protocol Developer Value Proposition
- A partner for distribution and sales
- Provide line-of-sight to compliance; de-risk new protocol deployment
For more information, visit the company’s website at www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
